At LEO Pharma Research & Development (R&D), we discover and develop novel therapies within the LEO focus areas dermatology and critical care, and as one of the world’s leading companies within dermatology, it is our ambition to function as a centre of expertise for the treatment of psoriasis, eczema and actinic keratosis.
We devote our entire R&D efforts to develop innovative drugs within these therapeutic focus areas. Our current R&D projects focus on:
- Actinic keratosis
- Inflammatory indications
- Non-melanoma skin cancer
To ensure sufficient funding for our R&D activities, 14% of LEO Pharma's turnover is allocated to research and development of new drugs.